The genetic legacy each of us inherits is a powerful force -- and in a few extreme cases, it can be deadly. Still, thanks to science, genetics need not always be destiny, as Martha Teichner shows us in our Cover Story:
Amy and Brad Price’s home in Omaha, Nebraska, is crazy with all the kids around. There are seven of them, ages 2 to 11. But if you look closely, you’ll see small memorials to one more: Liviana, who died in 2013 at the age of 5½ of a rare, nightmare disease called late infantile metachromatic leukodystrophy. MLD destroys brain cells and is caused by a single, faulty gene.
“She was happy all the time,” Brad said.
Amy added, “She loved pretty dresses.”
“She loved her tutu,” Brad said.
She was talkative, addicted to “Caillou,” the animated TV series, a lively little girl, ‘til she was two. “Her knees were going a little knock-kneed,” Amy said. “And she had been just randomly falling down.”
Her doctor said, “Nothing to worry about,” but she quickly got worse.
“I was in the kitchen doing something and I heard her crying,” Amy recalled. “And I turned around and said, ‘Liviana, what’s wrong?’ And she said, ‘Mommy, my legs don’t work.’”
Liviana was diagnosed in the fall of 2010. Amy recalled: “She’s sitting on the bed in her tutu and her colorful sweater, and they’re telling me she’s gonna die.”
Many children with the disorder are dead by the age of 6. And it runs in families. If it hadn’t been for Liviana, Amy and Brad Price would never have known to have their other children tested. They learned that their infant son, Giovanni, had inherited the faulty gene, too.
“I get a call from the doctor’s office,” said Amy, “I knew. And I was thinking, ‘I’ve just been told two of my kids now are gonna die.’”
Except that’s not what happened.
Doing research online, Amy Price discovered the existence of a medical trial in Milan, Italy, of an extraordinary gene therapy treatment for MLD that would save Giovanni’s life -- and later, when his sister, Cecilia, was born with MLD, hers, too. The treatment works only on children who, like them, have not yet started showing symptoms.
The Price family scraped together the money to go to Milan.
“The patients go to the surgery room for collection of the stem cells on Monday, and receive their cells back on Friday evening,” said Dr. Alessandra Biffi, who oversaw the trial.
A patient’s stem cells contain the faulty gene, which the doctors have learned how to fix. Amazing, right? But then they need a vehicle to insert the good gene into the stem cells before those are put back into the patient’s body.
Here’s what’s really amazing: That vehicle is the HIV virus, re-engineered so the children can’t get AIDS.
Why the HIV virus? “Is it particularly efficient at getting around the body?” Teichner asked.
“Yeah, it’s very efficient in entering our cells, and that’s why we use it,” Dr. Biffi replied.
How well did the children do? It will take years to know for sure, but so far so good. “At least 70-80% of them have an outstanding benefit coming from the treatment,” Dr. Biffi said. “Some of the children were going to school and having a normal life.”
Giovanni Price is six now, in first grade. He and his sister Cecilia (Ceci for short) have to go back to Milan twice a year to be tested and monitored.
Brad Price calls Dr. Biffi “Our angel. She took us in like family.”
So why Italy, and not the United States?
Gene therapy has a checkered history. In the 1990s, hyped as the Next Big Thing, research withered here after serious setbacks,. But more than 15 years later, it’s back. One sign: Dr. Biffi is now head of the gene therapy program at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
Teichner asked, “Do you believe that gene therapy is finally coming into its own?”
“I think yes, absolutely,” Dr. Biffi replied.
The MLD trial, she thinks, demonstrates what’s possible -- offering promise to the 30 million Americans who suffer from some 7,000 rare diseases.
Trials for the experimental treatment Ceci and Giovanni Price received in Milan have not begun in the U.S. They are two of only 24 children in the world with MLD to receive it.
Compare Giovanni to Calliope Joy Carr, also six, from Bala Cynwyd, Pa., outside Philadelphia. She can turn her head, a little. She can still smile and laugh. But that’s about all. She was diagnosed at 2.
For her parents, college professors Patrick Carr and Maria Kefalis, coming to terms with the disease was wrenching. “It’s decline in slow motion, and that’s difficult,” said Carr.
“I remember the social worker said, ‘It’s good to try to cry in the shower to save it from your family and your children,’” Kefalis said.
After more than a year of rage and grief, Kefalis decided that she had to find some way of helping MLD children. It was too late for Cal, but she was desperate to give her daughter’s life meaning.
“We’re not wealthy people,” she said. “We didn’t know very influential people who could write a big check for a million dollars. And so we said, ‘Well, we’ll start selling cupcakes.’”
The Calliope Joy Foundation was formed in 2013. It’s been slow going, but the money added up. And when Kefalis learned about the Italian trial, and the fact that Amy Price had to keep going back to Milan with Giovanni and Ceci, it was clear she would use the money to help families get to Italy.
“She sent me a picture of Giovanni playing in his front yard,” Kefalis said. “He’s three months younger than Cal, so he should’ve been as sick as Cal. He should have been on a feeding tube. He should be paralyzed. And I thought, I gotta be a part of this. I need to help this happen again and again and again.”
Maria Kefalis has turned cupcakes into weapons of war -- her war against MLD. She’s raised more than $250,000, and helped where she could, but she’s hit a wall. So far, not a single gene replacement therapy has been approved by the FDA. The trial in Italy is closed to new patients. It could be years before any children with MLD will be allowed to receive the treatment in the United States.
“Now, it’s just impatience,” Kefalis said. “Now it’s, like, ‘When do we get this here? What will it take. Tell me what you need me to do.’”
Until then, she continues to fight her battles one cupcake at a time -- the Price children, Giovanni and Cecilia, proof to her the war can be won.
Teichner asked Brad and Amy Price, “You keep using the word ‘miracle.’ In what way is all of this a miracle?”
“Our son’s still with us, and Cecilia as well,” they replied. “That’s the miracle.”
- New hope for young patients with rare genetic disease (“CBS Evening News,” 10/16/15)
For more info:
- Leukodystrophy Center at Children’s Hospital of Philadelphia
- Calliope Joy Foundation
- Follow the Calliope Joy Foundation on Twitter, Facebook and Instagram
- Calliope Joy Foundation (Crowdrise)
- Liviana’s (and Giovanni’s) Journey (Blogspot)
- Alessandra Biffi, MD, director, gene therapy program, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center